Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, and exerts its biological functions on neurons predominantly through the TrkB receptor tyrosine kinase [1, 2] . Although BDNF/TrkB signaling is traditionally thought of in terms of synaptic plasticity and neuroprotection [3, 4] , accumulating evidence indicates that these molecules are also critical for antidepressant drug efficacy. Accumulating evidence supports the neurotrophin hypothesis in depression. For instance, antidepressant treatment induces BDNF mRNA expression, as well as autophosphorylation and activation of TrkB in the brain [5, 6] , and the behavioral effects of antidepressants in the forced swim test (FST) are attenuated in mice with only one active BDNF allele (BDNF
Primary Rat Cortical Neuron Culture
Cortical primary neurons were dissected from an E18 embryo and cultured, and the cortex was extirpated, cross-chopped and suspended by gently pipetting for separation in DMEM containing 5% fetal calf serum and 5% horse serum. The cell suspension was then centrifuged at 250 g for 5 min. This operation was repeated again. Cells were seeded into polyethyleneimine-coated 10-cm dishes and 12-well plates including coated coverslips and incubated at 37 ° C in 5% CO 2 /95% air. After 3 h, culture medium was changed to Neurobasal containing B-27 supplement (Invitrogen) and incubated for 4 days. For maintenance, half the medium was changed to fresh Neurobasal/B-27 every 4 days. After 1 week, the cultured neurons were used in drug treatment experiments.
Forced Swim Test
The FST assay is routinely performed in our lab. The experiment was conducted as previously described [14] . Adult male mice (2-3 months old) were randomly submitted to an FST without a preswim. Saline and methylated derivatives (5 mg/kg, 250 μl) were orally administrated by gavage for 21 days. The mice were allowed to adapt to the test room for 2 days. They were placed in a clear glass cylinder with a diameter of 16 cm, half-filled with clear water at 24 ° C (water depth of 14 cm, and the mice were not allowed to reach the bottom of the cylinder; water was changed after each mouse) for a total of 6 min (with 2 min of preswim), and immobility was recorded during the last 4 min by an investigator blind to the genotype and treatment.
Tail Suspension Test
Among 3 well-established behavioral assays [FST, tail suspension test (TST), and learned helplessness] to examine the antidepressant effect, TST is a well-accepted and easy depression-like behavioral experimental paradigm [16] . Briefly, adult male mice (2-3 months old) were treated with saline and methylated derivatives (5 mg/kg) via oral gavage for 21 days. The total duration of immobility induced by tail suspension was measured according to the method described [17] . After chronic drug treatment, both acoustically and visually isolated mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Mice were considered immobile only when they hung passively and completely motionless. Immobility time was manually recorded during a 6-min period by an experienced observer. The observer was in the room where experiments were performed and was blind to the condition of the animals.
Neurogenesis Analysis in TrkB Agonist-Treated Hippocampus
Adult male mice (2-3 months old) were orally administered with saline, compound C, D and 7-methoxy-8-hydroxyflavone (H428; 5 mg/kg) for 21 days. Then BrdU (50 mg/kg) was intraperitoneally injected. Within 2 h, the mice were perfused with 4% paraformaldehyde. Immunohistochemical staining was performed on formalin-fixed paraffin-embedded sections. Sections of the brain were cut, deparaffinized in xylene, and rehydrated in graded alcohols. The slides were boiled in 10 mmol/l citric acid (pH 6.0) for 10 min, followed by incubation in 2 N HCl for 10 min at room temperature. The slides were then permeabilized and blocked with 1% BSA in 0.2% PBS Tween 20. The incorporated BrdU was stained using anti-BrdU-FITC (Abcam, USA, 1: 50) at 4 ° C overnight. After three washes in PBS, the cells were stained with DAPI for another 10 min at room temperature. The slides were finally mounted with AquaMount (Lerner Laboratories, USA) containing 0.01% 1,4-diazobicyclo(2,2,2)octane and examined under a fluorescent microscope.
Immunohistochemistry Staining
Brain tissues were fixed in 4% paraformaldehyde overnight followed by paraffin embedding.
Sections of 6 μm were cut. For immunohistochemical staining, brain sections were deparaffinized in xylene and rehydrated in graded alcohols. Endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 5 min and all slides were boiled in 10 mmol/l sodium citrate buffer (pH 6.0) for 10 min. Phosphorylated TrkB816 and TrkB were detected using specific antibodies. Paraffin sections were deparaffinized in xylene and rehydrated gradient ethanol solution. Samples were boiled in 10 mmol/l sodium citrate buffer for 20 min to retrieve antigen. Brain sections were incubated with anti-TrkB (BD Biosciences) 1: 50, p-TrkB 1: 200 dilution at 4 ° C overnight. After washing with PBS 3 times, TrkB and phosphorylated TrkB816 were detected using specific primary antibodies and the Zymed Histo-SP AEC kit. Slides were then counterstained with hematoxylin.
In vivo Pharmacokinetic Study (CRO by Cerep, Inc.) Two-month-old male CD-1 mice (20-30 g) were obtained from Charles River Laboratories. The mice were divided into two groups: vehicle control and 7,8-DHF. 7,8-DHF was dissolved in water and 50 mg/kg of the dose was administered orally. Each animal was subjected to one blood draw and one brain collection. We had 3-, 10-, 30-, 60-, 120-, 240-, 360-and 480-min time points with 3 mice at each time point. For fasting, food but not water was withheld for at least 3-4 h. Following fasting, each mouse was weighed and the dose was calculated according to body weight. After administration of a test compound, food but not water was withheld for a further 1-2 h. Blood was collected via cardiac puncture. Blood aliquots (300-400 μl) were collected in tubes coated with lithium heparin, mixed gently, then kept on ice and centrifuged at 2,500 g for 15 min at 4 ° C within 1 h of collection. The plasma was harvested and kept frozen at -20 ° C until further processing. The brain sample was rinsed with cold saline, weighed, and kept on ice until further processing within 1 h of collection. Each brain was homogenized in 1.5 ml cold PBS for 10 min on ice using Power Gen 125. The brain homogenate from each brain was then stored at -20 ° C until further processing. The following are standard procedures for the HPLC-LC/MS/MS.
Statistics
Statistical analyses were performed using either Student's t test or one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison tests versus controls by the computer program GraphPad Prism (GraphPad Software, USA). Results were expressed as mean ± SEM and were considered as significant when p < 0.05.
Organic Synthesis of Compound C and Compound D
The compounds were synthesized following the methods described in our previous publication [14] .
Preparation of Compound 2
To the solution of compound 1 (2.0 g, 10.98 mmol, 1.0 Eq) in DMF (20 ml) Li 2 CO 3 (1.22 g, 16.47 mmol, 1.5 Eq) and BnBr (2.25 g, 13.18 mmol, 1.2 Eq) were added. It was stirred at 60 ° C overnight. TLC and LC/MS showed that BnBr reacted with the two free OH groups. Two regioisomers and a bibenzylated product were formed. The Li 2 CO 3 was filtered off and the solvent was removed under reduced pressure, after which water was added and extracted with EA 2 times. The organic phase was dried, filtered and concentrated. It was purified by a column chromatography for 1.1 g of crude product (containing some of the dibenylated product, 1 HNMR showed the desired product should be 70%) ( 
Preparation of Compound 6
To the solution of compound 5 (12 g, 70 mmol, 1.0 Eq) in DMF (180 ml) Li 2 CO 3 (5.9 g, 70 mmol, 1.0 Eq) was added. Then 1-(bromomethyl)benzene (11.7 ml, 1 mol) was added dropwise. The solution was stirred at 60 ° C overnight under N 2 . TLC showed the reaction was complete. It was quenched with water and extracted with EA. The organic phase was dried, filtered, and concentrated. 
Preparation of Compound 7
To the solution of compound 6 (4.4 g, 1.0 Eq) in acetone (140 ml) K 2 CO 3 (14.1 g, 6.0 Eq) and (MeO) 2 SO 4 (1.39 g, 0.5 Eq) were added. The reaction mixture was stirred at 5 ° C overnight. TLC showed the starting material and the desired product. It was quenched with water and extracted with EA. The organic phase was dried, filtered and concentrated. It was purified by column chromatography to get 1. 
Preparation of Compound 8
To the solution of compound 7 (1.0 g, 1.0 Eq) in THF (50 ml) t-BuOK (907.6 mg, 8.09 mmol, 2.2 Eq) was added at 0 ° C. Then the mixture was stirred for 30 min and 4-(dimethylamino)benzoyl chloride (742.7 mg, 4.04 mmol, 1.1 Eq.) in THF (8 ml) was added. It was stirred for 3 h. LC/MS showed the reaction was complete. It was quenched with water and extracted with EA. The organic phase was dried, filtered, and concentrated. 
Results

In vivo Pharmacokinetic Profiling and Metabolite Identification
Catechol group-containing compounds, such as catecholamine neurotransmitters, levodopa, and flavonoids, are subjected to extensive metabolic modification that includes conjugation (glucuronidation, sulfation, and methylation) and oxidation, leading to their low bioavailability and poor pharmacokinetic profiles. Oral administration of 7,8-DHF or its synthetic derivative 4 ′ -dimethylamino-7,8-DHF (4 ′ -DMA-7,8-DHF) evidently activates the TrkB receptor in mouse brain at 2 or 4 h and exhibits prominent antidepressant activity, which suggests a stimulatory effect on TrkB by either the compounds themselves or by their metabolites [14] . Therefore, we investigated 7,8-DHF in vivo pharmacokinetic profiles (after oral administration) at a 50 mg/kg dosage, which is 10-fold the widely used therapeutic dose. We chose this high dose in order to quantitatively obtain brain concentrations of the drug and its metabolites at late time points. Mouse plasma and brain samples were collected at different time points (3, 10, 30, 60, 120, 240, 360 and 480 min), subjected to acetonitrile precipitation, and analyzed by HPLC-MS/MS. Several major metabolites including 7-methoxy-8-hydroxy-flavone (7M8H-flavone) and two unknown peaks were detected in addition to the parent drug. The plasma 7,8-DHF concentration peaked at 10 min with 70 ng/ml, and brain 7,8-DHF also peaked at 10 min with a concentration of 50 ng/g of brain. 7,8-DHF in plasma was still detectable even at 8 h (5 ng/ml). However, in the brain, approximately 7 ng/g of 7,8-DHF was found at 4 h and it was below the quantitative limit at 6 h. The 7-position methylated metabolite (7M8H-flavone) was detected as early as after 3 min in the plasma. Its concentration was maximal at 10 min with 1.0 ng/ml, and it decreased to 0.2 ng/ml at 4 h. It was below the quantitative limit at 6 h. We failed to detect this metabolite in mouse brain at any time ( fig. 1 ). The T 1/2 for 7,8-DHF is 134 min with AUC last of 6,500 min·ng/ml and AUC Inf of 7,515 min·ng/ml. The in vivo pharmacokinetic profiles are summarized in table 1 .
In addition, we also monitored 7,8-DHF and Caco-2 permeability of its synthetic lead 4 ′ -DMA-7,8-DHF, which is a good predictor of human oral bioavailability. The appar- Pharmacokinetic parameters were derived from the noncompartmental model using WinNonlin 5.2. T max = Time of maximum observed concentration; C max = concentration corresponding to T max ; T 1/2 = elimination half-life; AUC last = area under the concentration-time curve from the time of dosing to the time of last observation that is greater than the limit of quantitation; AUC Inf = area under the concentration-time curve from the time of dosing, extrapolated to infinity; terminal point = number of observations used to calculate the terminal slope.
1 Linear/log trapezoidal method was used for AUC calculation. in table 2 . Notably, the addition of the dimethylamino group on the 4 ′ -position of the B ring increased the efflux of the lead compound, indicating a reduction of oral bioavailability.
Identification of the Methylated Metabolites in Plasma and Mouse Brain
In order to identify the other metabolites, we conducted LC/MS/MS with the plasma samples at 30 min. Full scan HPLC-MS analysis was performed and total ion current chromatograms from the test and control samples were compared. Retention times, peak areas, and the respective MS spectra of the species detected in the test samples, but not in the control samples, were identified and recorded. The retention time on HPLC for the authentic metabolite H428 was 2.8 min. The identities of the compounds with retention times of 2.92 and 2.66 min remained unclear ( fig. 2 a) . In order to get more information about the chemical structure of the additional peaks, a product ion scan was performed. The 2.66-min peak had a broad, uneven profile and its elution time was earlier than in the tandem MS analysis; also, no product ions were observed in the spectrum. Based on this observation and the fact that a similarly intense, broad peak was seen in the control plasma sample, the 2.66-min peak was attributed to the matrix itself and was not thought to be related structurally to 7,8-DHF or H428. Since the product ion spectrum of the standard (H428) and the 2.92-min peak from numerous mouse samples were very similar, and the molecular weight was the same, 268 (m/z 269), we concluded that this peak represented the other methylated isomer, 7-hydroxy-8-methoxyflavone ( fig. 2 b-d 
The Metabolite, 7M8H-Flavone, Activates the TrkB Receptor in Primary Neurons and Mouse Brain
To explore whether the methylated metabolite could activate the TrkB receptor in primary neurons, we compared the mono-methylated H428 and dimethylated 7,8-DHF (D024) with their 4 ′ -DMA-7,8-DHF counterparts. As we previously reported, 4 ′ -DMA-7,8-DHF displayed more robust TrkB agonistic activity than 7,8-DHF. We made a similar observation for 4 ′ -DMA-H428 versus H428. Interestingly, the dimethylated derivatives also somehow triggered TrkB activation ( fig. 3 a, b) . BDNF was included as a positive control for validating TrkB activation in primary neurons by the lead compound ( fig. 3 b, lower panels) . To assess whether the methylated H428 could trigger TrkB activation in mouse brain, we treated C57BL/6J mice with 5 mg/kg of various compounds via oral gavage. The brain samples were collected 2 h after drug treatment. Immunoblotting analysis demonstrated that both 7,8-DHF and H428 clearly activated the TrkB receptor compared to vehicle control. The dimethylated 7,8-DHF (D024) also elicited TrkB activation (p-TrkB Y816), but the effect was not as strong as that of the other two compounds ( fig. 3 c, top panel) . However, p-TrkB 706 immunoblotting demonstrated that D024 elicited the strongest p-TrkB signal ( fig. 3 c, 2nd panel) . The p-Akt ELISA assay showed that the downstream Akt signal was activated by these compounds as well ( fig. 3 c,  bottom panel) . We conducted the same experiments with 4 ′ -DMA-7,8-DHF derivatives with oral dosing of 1 mg/kg. We observed a similar trend of p-TrkB activation in brain lysates ( fig. 3 d, top panel) . Both 4 ′ -DMA-7,8-DHF and its mono-methylated derivative potently activated Akt, whereas the dimethylated derivative failed to do so ( fig. 3 d, bottom panel) . Therefore, the 7-methylated metabolite of 7,8-DHF activates TrkB signaling in primary neurons and mouse brain.
Inhibition of COMT Reduces TrkB Activation by 7,8-DHF or 4 ′ -DMA-7,8-DHF
To ascertain whether COMT is responsible for the methylation of 7,8-DHF, we employed two COMT inhibitors that include tolcapone and entacapone, which are commonly used in the treatment of Parkinson's disease [18] . The optimal dose schedule for these two inhibitors has previously been extensively studied in rodents [19, 20] . Following the experimental schemes, we pretreated mice with 30 mg/kg of the two inhibitors via oral gavage 1 h before 7,8-DHF or 4 ′ -DMA-7,8-DHF administration, since this has been reported as a favorable dosage for COMT inhibitors [21] . Two hours after flavonoid treatment, we collected the brain samples and fig. 4 a, 3rd left panel). Since 30 mg/kg of COMT inhibitors alone triggered TrkB phosphorylation and shadowed the agonistic effect by two small agonists, we lowered the dose of the inhibitors to 10 mg/kg to reduce their effect on TrkB activation. We found entacapone at 10 mg/kg was still able to diminish the agonistic effect by 4 ′ -DMA-7,8-DHF, whereas tolcapone lost its inhibitory activity in suppressing TrkB phosphorylation by these two small agonists ( fig. 4 a, middle and right panels). p-Akt ELISA analysis also confirmed our observation in the immunoblotting assay. There are no significant changes between control versus 7,8-DHF or 4 ′ -DMA-7,8-DHF in both the entacapone-treated and tolcapone-treated groups ( fig. 4 b) . Hence, methylation of 7,8-DHF might mediate the agonistic effect of 7,8-DHF in mice.
7M8H-Flavone and Synthetic O-Methylated Derivatives Display Antidepressant Effects
To explore whether the methylated derivatives also possess the agonistic effect, we synthesized several 4 ′ -position substitute derivatives and examined their TrkB stimulatory effect on primary neurons. The organic synthetic routes are summarized in figure 5 a. Oral administration of two compounds at a 1 mg/kg dosage robustly fig. 5 b) . FST and TST are well established behavioral assays used to examine antidepressant effects. We have shown that both 7,8-DHF and its lead compound 4 ′ -DMA-7,8-DHF robustly decreased the immobility in FST after chronic treatment [14] . To investigate whether these methylated derivatives possess any antidepressant effect, we conducted a chronic experiment by consecutively treating the mice with 5 mg/kg of drugs for 21 days (orally, once a day). In an FST assay, all three compounds significantly reduced the immobility with H428 exhibiting the strongest effect ( fig. 5 c, left panel) . In a TST assay, both H428 and compound C substantially decreased the immobility, whereas compound D lowered the immobility, but the reduction was not statistically significant ( fig. 5 c, right panel) . Notably, acute drug treatment had no effect on immobility, which is different from traditional SSRI or tricyclic antidepressants (data not shown). Moreover, we monitored locomotor activity after 3 weeks of drug treatment, and found compound D significantly increased the locomotor activity compared to vehicle control or H428, compound C ( fig. 5 d) . Presumably, compound D might reduce immobility by increasing the locomotor activity. Thus, the 7-methylated H428 and compound C activate the TrkB receptor and display a prominent antidepressant effect.
7M8H-Flavone and Synthetic O-Methylated Derivatives Activate TrkB and Enhance Neurogenesis in the Hippocampus
BDNF is capable of enhancing neurogenesis; intrahippocampal infusion of BDNF into the hippocampus of adult rats increases the production of new neurons [22] and chronic (but not acute) antidepressant administration increases BDNF expression and neuro genesis. To examine whether chronic treatment with the methylated derivatives regulates neurogenesis, we conducted a BrdU incorporation assay by intraperitoneally injecting BrdU 2 h before sacrificing the animals. We found 3 weeks of drug treatment, with both H428 and compound C, significantly promoted neurogenesis compared to vehicle, whereas compound D also elevated neurogenesis but the result was not statistically significant ( fig. 6 a, b) . Immunohistochemistry staining with p-TrkB and total TrkB antibodies also demonstrated that both H428 and compound C strongly provoked TrkB phosphorylation in the dentate gyrus in the hippocampus. Nonetheless, the p-TrkB signal by compound D was not as strong as those of H428 and compound C ( fig. 6 c) . Hence, chronic treatment with methylated derivatives enhanced TrkB activation and triggered neurogenesis in the hippocampus.
Discussion
In the current report, we show that 7,8-DHF can penetrate the BBB and its major metabolites in plasma are O-mono-methylated and O-glucuronidated metabolites. In the brain, 7,8-DHF and one mono-methylated metabolite (7-hydroxy-8-methoxyflavone) are also detected. Interestingly, blockage of COMT with two different inhibitors reduces the TrkB stimulatory activity by 7,8-DHF or the lead compound 4 ′ -DMA-7,8-DHF in mouse brain, indicating that the methylated metabolites contribute to TrkB receptor activation upon oral administration of 7,8-DHF. Interestingly, the methylated metabolite H428 activates the TrkB receptor in primary neurons and in mouse brain after oral administration, underscoring the observation that methylated metabolites trigger TrkB receptor activation. As expected, chronic treatment with the methylated metabolite H428 or its synthetic derivatives for 3 weeks signific antly reduces the immobility in two types of antidepressant behavioral assays, which were accompanied with evident TrkB phosphorylation in the hippocampus and demonstrable neurogenesis. These observations support the notion that the active methylated metabolite induces chronic TrkB activation and prominent neurogenesis, leading to a robust antidepressant effect.
Since oral administration of 7,8-DHF or its synthetic derivative 4 ′ -DMA-7,8-DHF provokes TrkB activation at 1-2 h and the stimulatory effect is demonstrable even at 4 h in mouse brain, we investigated its in vivo pharmacokinetic profiles. The C max of 7,8-DHF in plasma peaked at 10 min with 70 ng/ml, but it slowly decreased to 24 ng/ml at 4 h, and even at 8 h, 5 ng/ml of 7,8-DHF was detected, indicating that it is orally bioavailable. Although its bioavailability is low, it is metabolized at a much slower pace when its concentration is low. On the other hand, both the methylated metabolite concentrations are relatively low compared to the parent 7,8-DHF, suggesting that glucuronidation but not methylation may be the main metabolism. Interestingly, the 8-methoxy-metabolite possesses a 148-min half-life versus 92 min for 7-methoxy-metabolite in plasma, indicating that 8-methoxy-7-hydroxyflavone is more metabolically stable than 8-hydroxy-7-methoxyflavone (H428). In brain samples, 7,8-DHF also peaks at 10 min with about 52 ng/g of brain, and decreases to 18 ng/g at 30 min, after which it remains relatively stable until 240 min (7 ng/g). Surprisingly, the 7-methoxy-metabolite (H428) is below the limit of quantification in the brain, whereas the 8-methoxy-metabolite is observable as early as 3 min after oral administration and detectable even at 240 min ( fig. 1 ) . Conceivably, if the methylated metabolites contribute to the in vivo TrkB agonistic effect by fig. 2A ). On the other hand, 7,8-DHF also stimulated TrkB activation in a dose-dependent manner. TrkB phosphorylation was prominent at a concentration of 100 nmol/l [14, 23] . Remarkably, when 3 nmol/l BDNF was mixed with various concentrations of 7,8-DHF, the mixture displayed much higher TrkB phosphorylation signals than when the same dose of BDNF or 7,8-DHF was employed separately (online suppl. fig. 2B ). Therefore, there is a synergistic effect between 7,8-DHF and BDNF in provoking TrkB receptor activation. Conceivably, these two molecules bind to different sites on TrkB extracellular domain and trigger an optimal TrkB activation conformation, leading to higher TrkB activation signals than when these molecules interact independently with the receptor. Levodopa, a precursor of catecholamines, is an important substrate of COMT. COMT inhibitors, like entacapone, protect levodopa from COMT, which prolongs the action of levodopa. Entacapone is a widely used adjunct drug of levodopa therapy. When given with an inhibitor of dopa decarboxylase (carbidopa or benserazide), levodopa is protected further. This 'triple therapy' is becoming a standard in the treatment of Parkinson's disease. Remarkably, we noticed that entacapone or tolcapone pretreatment elicited a higher TrkB phosphorylation baseline than vehicle control, indicating that these COMT inhibitors themselves might somehow induce TrkB activation in mouse brain, concealing the agonistic effect by 8-DHF ( fig. 3 ) . It is not surprising that both COMT inhibitors somehow elevate TrkB activation in mouse brain, because both of them contain the catechol group as does 7,8-DHF. In addition, our previous structure-activity relationship study shows that the catechol group in 7,8-DHF mediates its TrkB agonistic effect [14] . We found that 6,7-dihydroxyflavone and 6,7,3 ′ -trihydroxyflavone but not 5,6-dihydroxyflavone or 5,7-dihydroxyflavone possess a TrkB agonistic effect, suggesting that para-and meta-positions of dihydroxy groups on the A ring relative to the ketone group in the C ring of flavonoids are critical for stimulating the TrkB receptor [14] . These chemical structure characteristics are well in alignment with the backbone structure of tolcapone. Although entacapone does not contain the ketone group attached to the nitrocatechol functional group, it contains the highly conjugated structures, similar to the conjugated B and C rings in flavone compounds.
So far, a few small peptides and compounds have been reported to activate the TrkB receptor and might act as TrkB agonists [24, 25] . Nonetheless, these molecules do not fully imitate BDNF or regulate TrkB physiological functions in animals. However, our lead compound 7,8-DHF has been extensively demonstrated to mimic BDNF and exert a variety of neurological actions in numerous models including PD, stroke [12] , depression [13, 14, 26] , learning and memory [27, 28] . Chronic treatment with 7,8-DHF reveals no demonstrable toxicity, supporting safety at a dose of 5 mg/kg [14] . In addition, most recently, it has been shown to stimulate the LTP in aged rats through the TrkB receptor [29] . Notably, this compound exhibits therapeutic efficacy in a mouse model of Rett syndrome, which is caused by mutations in MeCP2, leading to reduced levels of BDNF in the brain [30] . Taken together, this evidence supports the notion that 7,8-DHF indeed mimics BDNF and possesses more prominent physiological activities in various animal models than other reported peptidomimetics or small molecules, supporting the fact that 7,8-DHF is a superior compound, with oral bioavailability, for TrkB agonist drug development.
